Old Web
English
Sign In
Acemap
>
authorDetail
>
Klas Bergenheim
Klas Bergenheim
AstraZeneca
Survival analysis
Placebo
Medicine
cost effectiveness
Type 2 diabetes
2
Papers
37
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial.
2021
Diabetes, Obesity and Metabolism
Phil McEwan
Angharad R. Morgan
Rebecca Boyce
Klas Bergenheim
Ingrid Gause-Nilsson
Deepak L. Bhatt
Lawrence A. Leiter
Peter A. Johansson
Ofri Mosenzon
Avivit Cahn
John P H Wilding
Show All
Source
Cite
Save
Citations (3)
Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
2020
European Journal of Heart Failure
Phil McEwan
O Darlington
John J.V. McMurray
Pardeep S. Jhund
Kieran F. Docherty
Michael Böhm
Mark C. Petrie
Klas Bergenheim
Lei Qin
Show All
Source
Cite
Save
Citations (34)
1